Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

With the elimination of malaria now considered a realistic goal, it would be useful for scientists and policy makers to have an inventory of the arsenal of antimalarials, current and prospective, that could help make this goal a reality. In order to provide an overview of antimalarial projects in recent clinical development, we review here the global portfolio of antimalarial drugs in clinical phases of development complemented by projects in the preclinical and early discovery phases. The portfolio is discussed in terms of the novelty of the new molecules and their potential health impact in terms of addressing the requirements for the control and eventual eradication of malaria.

Original publication

DOI

10.1038/clpt.2009.51

Type

Journal

Clinical pharmacology and therapeutics

Publication Date

06/2009

Volume

85

Pages

584 - 595

Addresses

UNICEF/UNDP/WB/WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland. olliarop@who.int

Keywords

Humans, Malaria, Falciparum, Antimalarials, Drug Approval, Drug Resistance, Drug Industry, World Health, World Health Organization, Clinical Trials as Topic, Drug Discovery